| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | October 3, 2024 4:30 P.M. |
| Form: | S-3 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | October 3, 2024 4:30 P.M. |
| Form: | S-3 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
PRE 14A - Glucotrack, Inc. (0001506983) (Filer)
8-K - Glucotrack, Inc. (0001506983) (Filer)
EFFECT - Glucotrack, Inc. (0001506983) (Filer)
3 - Glucotrack, Inc. (0001506983) (Issuer)
4 - Glucotrack, Inc. (0001506983) (Issuer)
4 - Glucotrack, Inc. (0001506983) (Issuer)
RUTHERFORD, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc.("Glucotrack", or the "Company") (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that the US Patent and Trademark Office (USPTO) has issued Patent Nos. US 12,453,494, US 12,458,257, and US 12,458,258 for the Company's continuous blood glucose monitoring (CBGM) platform. The patents strengthen Glucotrack's competitive position and intellectual property protection as the Company advances its multi-year, fully implantable CBGM system toward commercialization. The three patents protect key technologies in Glucotra
Rutherford, NJ., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) (the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 1,033,591 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,067,182 shares of common stock at an effective combined price of $3.87 per share and common warrant for aggregate gross proceeds of approximately $4.0 million, before deducting placement agent fees and other offer
Company to submit Investigational Device Exemption (IDE) to FDA for novel CBGM technology in Spring 2026 Expanded clinical advisory team with appointment of pain management and medical technology expert, Usman Latif, MD, MBA Strengthened balance sheet, cash and cash equivalents expected to fund operations through March 2026, including long-term feasibility clinical trials and achievement of related milestones Rutherford, NJ, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results
4 - GlucoTrack, Inc. (0001506983) (Issuer)
Company to submit Investigational Device Exemption (IDE) to FDA for novel CBGM technology in Spring 2026 Expanded clinical advisory team with appointment of pain management and medical technology expert, Usman Latif, MD, MBA Strengthened balance sheet, cash and cash equivalents expected to fund operations through March 2026, including long-term feasibility clinical trials and achievement of related milestones Rutherford, NJ, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results
RUTHERFORD, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc.("Glucotrack", or the "Company") (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Usman Latif, MD, MBA, has been named to Glucotrack's clinical advisory team, providing strategic counsel as the Company advances its epidural glucose monitoring applications alongside its continuous blood glucose monitor (CBGM). "Dr. Latif is a prominent pain management specialist and opinion leader with deep expertise in neuromodulation and treatment of Painful Diabetic Neuropathy (PDN). His exceptional knowledge in pain man
On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 Investigational Device Exemption submission to FDA of novel CBGM technology in Q4 2025 Strengthened Board of Directors, expands clinical advisory board, and established a Patient Advisory Board Improved capital structure, cash and cash equivalents expected to fund operations through 2025, including initiation of OUS clinical trials and achievement of related milestones Rutherford, NJ, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focu
1-for-5 reverse stock split to become effective as of the opening of trading onMay 20, 2024 Rutherford, NJ, May 15, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will effect a 1-for-5 reverse stock split (the "Reverse Stock Split") of its issued and outstanding common stock (the "Common Stock"), effective with the opening of trading on Monday, May 20, 2024. Glucotrack's Common Stock will continue to trade on the Nasdaq Capital Market ("Nasdaq") under the symbol "GCTK". The new CUSIP number
SC 13G - Glucotrack, Inc. (0001506983) (Subject)
SC 13G - GlucoTrack, Inc. (0001506983) (Subject)